Home
AI
World
Politics
Health
Crime & justice
Science & technology
Social issues
Sports
Money
Entertainment
Environment/energy
Military
Culture
Weather
Media






Home
Bias Split
Public FiguresControversies

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

Sign Up!
Sign Up Now!

How our sliders workAboutContact UsNewsletter Archive
MediaFAQGlossaryPrivacy Policy
  1. Home

Study: Paxlovid May Reduce Long COVID Risk

  • #Diseases & conditions
  • #Medicine & healthcare
  • #Research
  • #Pharmaceuticals
  • #COVID-19
story
NOV 2022
Image copyright: forbes
story last updated NOV 2022

The Spin

Narrative A

This study is a major breakthrough, highlighting the many positive impacts Paxlovid can have for COVID patients. It also provides data for researchers to further investigate how reducing viral load early can lessen the effects of, or even prevent, long COVID. Long-sought treatments for long COVID may finally be on the horizon.

Washington Post

Narrative B

We should be careful not to overstate the impact of this study. Nearly 75% of the participants were white men with an average age of 65, so it's a small sample size. Long COVID conditions weren’t eliminated, and in some cases, they weren't prevented. There’s still a lot of work to do, and for now, Paxlovid should be a part of a suite of approaches.

New York Times

Articles on this story

New VA study finds Paxlovid may cut the risk of long COVID
NPR Online NewsJUL 2022
Paxlovid Associated With 26% Lower Long Covid Risk, Here Are The Study’s Limitations Though
ForbesJUL 2022
Paxlovid may reduce long covid risk for some patients, VA study finds
Washington PostJUL 2022